NCT03709719View on ClinicalTrials.gov

Blinatumomab in High-risk B-cell Precursor Acute Lymphoblastic Leukemia

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

95

Participants

Timeline

Start Date

October 20, 2018

Primary Completion Date

October 30, 2026

Study Completion Date

October 30, 2028

Conditions
Acute Lymphoblastic Leukemia, Adult B-Cell
Interventions
DRUG

Blinatumomab Injection

Blinatumomab 28 μg/day : D1 to D28

Trial Locations (1)

75010

Hopital saint Louis, Paris

All Listed Sponsors
lead

Assistance Publique - Hôpitaux de Paris

OTHER

NCT03709719 - Blinatumomab in High-risk B-cell Precursor Acute Lymphoblastic Leukemia | Biotech Hunter | Biotech Hunter